DK0792154T3 - Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna) - Google Patents

Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)

Info

Publication number
DK0792154T3
DK0792154T3 DK95939282T DK95939282T DK0792154T3 DK 0792154 T3 DK0792154 T3 DK 0792154T3 DK 95939282 T DK95939282 T DK 95939282T DK 95939282 T DK95939282 T DK 95939282T DK 0792154 T3 DK0792154 T3 DK 0792154T3
Authority
DK
Denmark
Prior art keywords
dithio
bis
cisplatin
dimesna
ethanesulfonate
Prior art date
Application number
DK95939282T
Other languages
English (en)
Inventor
Peddaiahgari Seetharamulu
Frederick Herman Hausheer
Kochat Haridas
Dhanabalan Murali
Dasharatha Gauravaram Reddy
Original Assignee
Bionumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0792154T3 publication Critical patent/DK0792154T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK95939282T 1994-11-14 1995-11-14 Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna) DK0792154T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/338,379 US5789000A (en) 1994-11-14 1994-11-14 Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
PCT/EP1995/004490 WO1996014852A1 (en) 1994-11-14 1995-11-14 Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)

Publications (1)

Publication Number Publication Date
DK0792154T3 true DK0792154T3 (da) 2003-08-04

Family

ID=23324592

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95939282T DK0792154T3 (da) 1994-11-14 1995-11-14 Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)

Country Status (13)

Country Link
US (5) US5789000A (da)
EP (1) EP0792154B1 (da)
JP (3) JP4171526B2 (da)
KR (1) KR100411380B1 (da)
CN (2) CN1165483B (da)
AT (1) ATE237337T1 (da)
AU (1) AU706181B2 (da)
CA (1) CA2202170C (da)
DE (1) DE69530412T2 (da)
DK (1) DK0792154T3 (da)
ES (1) ES2191717T3 (da)
PT (1) PT792154E (da)
WO (1) WO1996014852A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025488A (en) * 1994-11-14 2000-02-15 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
AU712548B2 (en) * 1996-09-23 1999-11-11 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
US6037336A (en) * 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6197831B1 (en) * 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US6034126A (en) * 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
US6156350A (en) * 1999-12-02 2000-12-05 Corazon Technologies, Inc. Methods and kits for use in preventing restenosis
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
WO2002036171A1 (en) * 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
MXPA03006359A (es) * 2001-01-19 2004-04-20 Bionumerik Pharmaceuticals Inc Metodo para tratamiento del cancer.
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
US6352979B1 (en) * 2001-08-20 2002-03-05 Lucinda Lizcano Method of treating snakebite and complications resulting therefrom
JP2005510471A (ja) * 2001-09-24 2005-04-21 トスク インコーポレーティッド 減少した毒性のシスプラチン製剤及びそれを使用する方法
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
WO2003082078A2 (en) * 2002-03-28 2003-10-09 Medical College Of Ohio Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040014730A1 (en) * 2002-07-10 2004-01-22 Frederick Hausheer Formulations and methods of reducing toxicity of anti-infective agents
EP1583540A4 (en) * 2002-12-21 2006-07-26 Bionumerik Pharmaceuticals Inc METHOD FOR THE TREATMENT OF TOXIC CHEMICALS EMITTED PATIENTS
EP1613308A4 (en) * 2003-03-27 2008-02-20 Lankenau Inst Medical Res CANCER TREATMENT METHODS
US7053240B2 (en) * 2003-12-17 2006-05-30 Bionumerik Pharmaceuticals, Inc. Process for synthesizing disulfides
JP5576592B2 (ja) * 2004-03-29 2014-08-20 キャンサー アドヴァンシズ インコーポレイテッド ガストリンホルモンに対するモノクローナル抗体
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US7282602B2 (en) * 2004-09-21 2007-10-16 Bionumerik Pharmaceuticals, Inc. Medicinal disulfide salts
US20060063742A1 (en) * 2004-09-21 2006-03-23 Hausheer Frederick H Method of treatment for or protection against lymphedema
US7235589B2 (en) 2004-09-21 2007-06-26 Bio Numerik Pharmaceuticals, Inc. Method of treating patients undergoing kidney dialysis
EP1794586B1 (en) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
AU2006326442B2 (en) * 2005-12-13 2012-03-01 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US20070219268A1 (en) * 2006-03-16 2007-09-20 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008097658A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
EP2178893A4 (en) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc ORAL FORMULATIONS FOR PICOPLATIN
US8765368B2 (en) * 2007-09-17 2014-07-01 The University Of Toledo Cancer risk biomarker
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
WO2009113989A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
JP5694782B2 (ja) * 2008-03-14 2015-04-01 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 肺癌、腺癌及び他の病状のための治療方法及び組成物
WO2009113984A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
EP2804602A4 (en) * 2012-01-20 2016-08-10 Dennis Brown USE OF SUBSTITUTED HEXITOLS WITH DIANHYDROGALACTITOL AND ANALOGUE FOR THE TREATMENT OF NEOPLASTIC DISEASES AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTFORME AND MEDULLOBLASTOMA
IN2015DN01369A (da) * 2012-07-19 2015-07-03 Relypsa Inc
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2806866C3 (de) * 1978-02-17 1981-02-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
ATE65402T1 (de) * 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum

Also Published As

Publication number Publication date
AU706181B2 (en) 1999-06-10
US5789000A (en) 1998-08-04
MX9703460A (es) 1997-07-31
JP2012211198A (ja) 2012-11-01
DE69530412D1 (de) 2003-05-22
ATE237337T1 (de) 2003-05-15
US5866169A (en) 1999-02-02
ES2191717T3 (es) 2003-09-16
KR970706830A (ko) 1997-12-01
CA2202170C (en) 2007-04-10
CN1165483A (zh) 1997-11-19
CA2202170A1 (en) 1996-05-23
US5866615A (en) 1999-02-02
WO1996014852A1 (en) 1996-05-23
AU4116896A (en) 1996-06-06
PT792154E (pt) 2003-09-30
US5902610A (en) 1999-05-11
DE69530412T2 (de) 2003-10-30
KR100411380B1 (ko) 2004-04-30
JP2008133304A (ja) 2008-06-12
EP0792154B1 (en) 2003-04-16
JP4171526B2 (ja) 2008-10-22
EP0792154A1 (en) 1997-09-03
JPH10509143A (ja) 1998-09-08
US5866617A (en) 1999-02-02
CN1165483B (zh) 2012-09-05
CN101987111A (zh) 2011-03-23

Similar Documents

Publication Publication Date Title
DK0792154T3 (da) Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)
DK0469013T3 (da) Hidtil ukendte arylpyridaziner, fremstilling deraf, anvendelse deraf og lægemidler indeholdende disse
PT1025845E (pt) Terapia com hidromorfona
HK1026909A1 (en) Substituted phenyl derivatives, their preparation and use
ES8802321A1 (es) Procedimiento para preparar peptidos difluorcetonicos
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
AU4484989A (en) Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents
GR3003068T3 (en) (2,2-bis(aminomethyl)-1,3-propanediol-n,n')platinum complexes
IT1230145B (it) Complessi di rutenio (iii) come agenti antineoplastici.
ECSP930949A (es) Derivados de 2- imidazolina -5- onas y 2- imidazolina- 5 tionas fungicidas
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
DE69940551D1 (de) Mercaptane und disulfide
DE3769910D1 (de) Verwendung von n, n'-bis-l-aminosaeure-l-cystinpeptiden in aminosaeure-praeparaten fuer orale und parenterale ernaehrung.
ES511753A0 (es) Un procedimiento para la preparacion de derivados de sucrosa'4-halo-sustituidos.
ES2020953B3 (es) Complejos de tetrahidro-3,4-furanodiamina-n-n'platino.
NO20006699L (no) Forbindelser med veksthormonfrigjörende egenskaper
DK0957920T3 (da) Reduktion af carboplatins toksiske effekt under anvendelse af dithioethere
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
ATE232723T1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
DE69905144D1 (de) N,N'-Diacylthiocystine
AR024131A1 (es) 3,6-dihidro-pirazolo[3,4-d] [1,2,3] triazin-4-onas de efecto anticonvulsivo, procedimientos para su preparacion, su utilizacion para la preparacion demedicamentos y las composiciones farmaceuticas que los contienen
BR9703451C1 (pt) Composto natural para o tratamento de diabete ecâncer etc
ZA858672B (en) New use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
KR920019354A (ko) 9-아미노-1,2,3,4- 테트라하이드로아크리딘-1-올 및 관련 화합물의 aids치료용 용도
IT8621925A0 (it) Composizioni farmaceutiche adattivita' antineoplastica.